{"id":174877,"date":"2026-09-27T10:24:12","date_gmt":"2026-09-27T10:24:12","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/174877\/"},"modified":"2026-09-27T10:24:12","modified_gmt":"2026-09-27T10:24:12","slug":"could-this-be-novo-nordisks-next-billion-dollar-weight-loss-product-3","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/174877\/","title":{"rendered":"Could This Be Novo Nordisk\u2019s Next Billion-Dollar Weight-Loss Product?"},"content":{"rendered":"<p>Key Points<\/p>\n<p>Novo Nordisk needs new products to better compete with Eli Lilly in the weight loss market.<\/p>\n<p>Zenagamtide is one of its promising candidates and could, eventually, generate over $1 billion in annual sales.<\/p>\n<p>Novo Nordisk&#8217;s deep pipeline makes it likely to remain a leader in this space over the medium term.<\/p>\n<p>Novo Nordisk&#8217;s (NYSE:NVO) semaglutide, sold under the brand names Wegovy and Ozempic, is one of the world&#8217;s best-selling compounds. Not that this has allowed the company to perform in line with broader equities over the past two years. The pharmaceutical giant has lost a little over 60% of its value over this period. Can Novo Nordisk bounce back?<\/p>\n<p>That largely depends on the company&#8217;s ongoing clinical development, and one of its candidates in particular, zenagamtide, looks highly promising. Novo is developing zenagamtide for obesity and diabetes. Could this be the next billion-dollar medicine for the Denmark-based drugmaker in its core therapeutic area?<\/p>\n<p>Missed AI\u2019s &#8220;Act 1&#8221;? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn&#8217;t buy Nvidia in 2005. But according to our analysts, we\u2019re only at the end of &#8220;Act 1&#8243;\u2014the R&amp;D phase. &#8220;Act 2&#8221; is the global rollout. <a href=\"https:\/\/api.fool.com\/infotron\/infotrack\/click?apikey=35527423-a535-4519-a07f-20014582e03e&amp;impression=10d3037a-bb6a-4e84-974c-df5b8fd45557&amp;url=https%3A%2F%2Fwww.fool.com%2Fmms%2Fmark%2Fa-sa-ai-boom-nvidias%3Faid%3D10891%26source%3Disaediica0000080%26ftm_cam%3Dsa-ai-boom%26ftm_veh%3Dtop_incontent_pitch_feed_partner%26ftm_pit%3D19998&amp;utm_source=globeandmail&amp;utm_medium=feed&amp;utm_campaign=article&amp;referring_guid=a52084c7-7188-47c3-95fb-4496f368dfc9\" referrerpolicy=\"no-referrer-when-downgrade\" rel=\"noopener nofollow\" target=\"_blank\">Continue \u00bb<\/a><\/p>\n<p>]]><img fetchpriority=\"high\" alt=\"Novo Nordisk logo overlaid on the company headquarters building\" decoding=\"async\" height=\"800\" loading=\"lazy\" src=\"https:\/\/barchart-news-media-prod.aws.barchart.com\/FC\/9f574917508ae41586078e03a3893fa6\/%3Furl%3Dhttps%253a%252f%252fcdn.content.foolcdn.com%252fimages%252f1umn9qeh%252fproduction%252f812914072bca01e887ba4bd85405a6b82f4c156a-1200x800.png%253fw%253d1200%2526h%253d800%2526q%253d75%2526auto%253dformat%26amp%3Bw%3D700\" style=\"width: 100%; height: auto; display: block;\" width=\"1200\"\/><\/p>\n<p style=\"margin-top: 0.5rem; font-size: 0.875rem; color: #666;\">Image source: The Motley Fool.<\/p>\n<p>Why zenagamtide&#8217;s progress is worth monitoring<\/p>\n<p>Novo Nordisk lost market share in its core therapeutic area to its biggest rival, Eli Lilly(NYSE:LLY). Also, competition from other <a href=\"https:\/\/www.fool.com\/investing\/stock-market\/market-sectors\/healthcare\/pharmaceutical-stocks\/?utm_source=globeandmail&amp;utm_medium=feed&amp;utm_campaign=article&amp;referring_guid=a52084c7-7188-47c3-95fb-4496f368dfc9\" target=\"_blank\" rel=\"noopener nofollow\">pharmaceutical giants<\/a> should intensify in this space in the coming years. Novo Nordisk still generates most of its revenue from its <a href=\"https:\/\/www.fool.com\/investing\/how-to-invest\/stocks\/glp-1-stocks\/?utm_source=globeandmail&amp;utm_medium=feed&amp;utm_campaign=article&amp;referring_guid=a52084c7-7188-47c3-95fb-4496f368dfc9\" target=\"_blank\" rel=\"noopener nofollow\">GLP-1<\/a> portfolio, and its pipeline is concentrated in diabetes and obesity, although it also has candidates in other areas, including rare blood diseases. So, Novo Nordisk has a lot riding on clinical and regulatory progress for its leading weight-loss candidates, including zenagamtide.<\/p>\n<p>This medicine mimics the actions of the gut hormones GLP-1 and amylin, both of which help regulate blood sugar and appetite. The dual hormonal pathway approach has proved highly successful with Eli Lilly&#8217;s Zepbound, a dual GLP-1 and GIP agonist, which is currently the market leader in weight loss. Of course, that doesn&#8217;t mean zenagamtide will also be successful, but so far the data point to the medicine potentially being highly effective. In a Phase 1b\/2a study, zenagamtide led to a weight loss of up to 24.3% in 36 weeks.<\/p>\n<p>Patients taking a placebo lost as much as 1.1% of their body weight in the study. By the standards of approved anti-obesity medicines, those are excellent results. True, it&#8217;s too early to celebrate. This was a fairly small early-stage trial with 125 participants. In larger clinical trials, zenagamtide&#8217;s performance might not be as strong. We should know that within the next couple of years. Zenagamtide is undergoing Phase 3 studies. Provided the results are impressive (the market will likely expect at least mid-20% weight loss), Novo Nordisk&#8217;s shares could soar.<\/p>\n<p>Can Novo catch up to its biggest competitor?<\/p>\n<p>If zenagamtide meets market expectations, it will likely generate well over $1 billion in annual sales. Here are three reasons why. First, it will prove much more effective than Wegovy and, arguably, even more so than Novo Nordisk&#8217;s CagriSema, which could soon earn approval. CagriSema beat Wegovy in a head-to-head obesity clinical trial, but it fell short of the 25% average weight loss that management was hoping for. If zenagamtide can succeed where even CagriSema failed, it might become Novo Nordisk&#8217;s biggest growth driver.<\/p>\n<p>Second, zenagamtide will help Novo better compete with Eli Lilly&#8217;s Zepbound, which has also proven more effective than CagriSema in a head-to-head Phase 3 obesity study. Perhaps zenagamtide will come closer to, or even exceed, Zepbound&#8217;s average weight-loss numbers. Third, zenagamtide is also being developed in an oral formulation.<\/p>\n<p>Novo&#8217;s oral Wegovy has proved popular since its launch in January, helping the company expand its market presence. A more effective weight loss pill could help Novo stay ahead of Eli Lilly in the oral anti-obesity niche.<\/p>\n<p>That said, Novo&#8217;s zenagamtide could fall short in its ongoing late-stage trials. That will likely sink the company&#8217;s stock. It&#8217;s worth noting that the Denmark-based drugmaker has several other exciting pipeline candidates. And it likely has the funds to acquire or license more from smaller drugmakers. So, even a failure with zenagamtide won&#8217;t mean the end of its ambitions in this market. Still, zenagamtide is important to Novo&#8217;s prospects.<\/p>\n<p>With that said, should investors purchase Novo&#8217;s stock right now? After losing significant market share, the company has massive upside if it can develop several newer and better weight loss drugs, and it boasts a deep pipeline that could allow it to significantly rejuvenate its approved lineup over the next five years. That&#8217;s why, even with the risk of clinical setbacks, <a href=\"https:\/\/www.fool.com\/investing\/how-to-invest\/stocks\/how-to-invest-in-novo-nordisk-stock\/?utm_source=globeandmail&amp;utm_medium=feed&amp;utm_campaign=article&amp;referring_guid=a52084c7-7188-47c3-95fb-4496f368dfc9\" target=\"_blank\" rel=\"noopener nofollow\">the stock is worth serious consideration<\/a>, especially at current levels and for investors willing to hold onto its shares for a while.<\/p>\n<p>Should you buy stock in Novo Nordisk right now?<\/p>\n<p>Before you buy stock in Novo Nordisk, consider this:<\/p>\n<p>The Motley Fool Stock Advisor analyst team just identified what they believe are the <a href=\"https:\/\/api.fool.com\/infotron\/infotrack\/click?apikey=35527423-a535-4519-a07f-20014582e03e&amp;impression=4d500360-ee06-420a-8b74-3b438b7f8c36&amp;url=https%3A%2F%2Fwww.fool.com%2Fmms%2Fmark%2Fe-sa-bbn-dyn-headline%3Faid%3D8867%26source%3Disaeditxt0001178%26company%3DNovo%2520Nordisk%26ftm_cam%3Dsa-bbn-evergreen%26ftm_veh%3Darticle_pitch_feed_partners%26ftm_pit%3D18725&amp;utm_source=globeandmail&amp;utm_medium=feed&amp;utm_campaign=article&amp;referring_guid=a52084c7-7188-47c3-95fb-4496f368dfc9\" referrerpolicy=\"no-referrer-when-downgrade\" rel=\"noopener nofollow\" target=\"_blank\">10 best stocks<\/a> for investors to buy now\u2026 and Novo Nordisk wasn\u2019t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.<\/p>\n<p>Consider when Netflix made this list on December 17, 2004&#8230; if you invested $1,000 at the time of our recommendation, you\u2019d have $386,781!* Or when Nvidia made this list on April 15, 2005&#8230; if you invested $1,000 at the time of our recommendation, you\u2019d have $1,379,943!*<\/p>\n<p>Now, it\u2019s worth noting Stock Advisor\u2019s total average return is 936% \u2014 a market-crushing outperformance compared to 213% for the S&amp;P 500. Don&#8217;t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.<\/p>\n<p><a class=\"ticker_pitch\" href=\"https:\/\/api.fool.com\/infotron\/infotrack\/click?apikey=35527423-a535-4519-a07f-20014582e03e&amp;impression=4d500360-ee06-420a-8b74-3b438b7f8c36&amp;url=https%3A%2F%2Fwww.fool.com%2Fmms%2Fmark%2Fe-sa-bbn-dyn-headline%3Faid%3D8867%26source%3Disaeditxt0001178%26company%3DNovo%2520Nordisk%26ftm_cam%3Dsa-bbn-evergreen%26ftm_pit%3D18725%26ftm_veh%3Darticle_pitch_feed_partners%26company%3DNovo%2520Nordisk&amp;utm_source=globeandmail&amp;utm_medium=feed&amp;utm_campaign=article&amp;referring_guid=a52084c7-7188-47c3-95fb-4496f368dfc9\" referrerpolicy=\"no-referrer-when-downgrade\" rel=\"noopener nofollow\" target=\"_blank\">See the 10 stocks \u00bb<\/a><\/p>\n<p class=\"disclaimer\" style=\"font-size: 0.65rem; color: #767676; margin-top: 5px; text-align: left;\">*Stock Advisor returns as of September 25, 2026. <\/p>\n<p><a href=\"https:\/\/www.fool.com\/author\/20111\/\" target=\"_blank\" rel=\"noopener nofollow\">Prosper Junior Bakiny<\/a> has positions in Eli Lilly and Novo Nordisk. The Motley Fool has positions in and recommends Eli Lilly and Novo Nordisk. The Motley Fool has a <a href=\"https:\/\/www.fool.com\/legal\/fool-disclosure-policy\/\" target=\"_blank\" rel=\"noopener nofollow\">disclosure policy<\/a>.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" width=\"1\" height=\"1\" style=\"display:none;\" referrerpolicy=\"unsafe-url\" src=\"https:\/\/barchart-news-media-prod.aws.barchart.com\/FC\/9f574917508ae41586078e03a3893fa6\/pixel%3Fslug%3Dmotleyfoolgm-2026-9-25-could-this-be-novo-nordisks-next-billion-dollar-weight-loss-product\"\/><\/p>\n","protected":false},"excerpt":{"rendered":"Key Points Novo Nordisk needs new products to better compete with Eli Lilly in the weight loss market.&hellip;\n","protected":false},"author":2,"featured_media":174878,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[2960,5921,5918,5917,5920,5919,5922,3860,272,4011],"class_list":["post-174877","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-eli-lilly-and-company","tag-futures","tag-index-market-quote","tag-index-market-quotes","tag-index-market-symbol","tag-index-market-symbols","tag-indices","tag-lly","tag-novo-nordisk","tag-the-globe-and-mail"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117342520651706415","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/174877","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=174877"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/174877\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/174878"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=174877"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=174877"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=174877"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}